Pliant Therapeutics price to sales ratio PLRX

Market value divided by revenue over the last twelve months, since 2021.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 192×; Nov 2023
6-year median: 73.5×
6-year range: 23.9× to 200×
Peer median: 0.9×

Pliant Therapeutics' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Nov 2023, at 192×.

On the days it had one over the last 6 years, its median was 73.5×, from 23.9× in May 2022 to 200× in Sep 2023.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	192×	96.3×	200×
2022	97.0×	23.9×	124×
2021	48.5×	25.5×	78.7×

Against its peers

Companies in Drug Manufacturers - General nearest Pliant Therapeutics' size, closest first, today.

Company	Price to sales ratio
PLRXPliant Therapeutics	n/m
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
NATRNatures Sunshine Products	0.4×
ARVNArvinas	1.5×
Peer median	0.9×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Pliant Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.